Targeting thioredoxin reductase: Anticancer agents and chemopreventive compounds

Medicinal Chemistry

Volumn 6, Issue 5, 2010, Pages 286-297

  Zeng, H H ^a   Wang, L H ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Alkylating agents; Antitumour agents; Ethaselen; Motexafin gadolinium; Redox system; Reversible TrxR inhibitor; Thioredoxin reductase; TrxR substrates

Indexed keywords

(2,2':6',2'' TERPYRIDINE)PLATINUM; 1 CHLORO 2,4 DINITROBENZENE; 9,10 PHENANTHRENE QUINONE; [1 PHENYL 2,5 DI(2 PYRIDYL)PHOSPHOLE]GOLD CHLORIDE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AURANOFIN; AUROTHIOGLUCOSE; BENZENESULFONYL 6F INDOLE; CARMUSTINE; CHETOCIN; CHLORAMBUCIL; CISPLATIN; CURCUMIN; DIAZIQUONE; EBSELEN; ETHASELEN; GADOLINIUM TEXAPHYRIN; JUGLONE; METHYLSELENINATE; MYRICETIN; NAPHTHALIMIDE DERIVATIVE; NAPHTHALIMIDE TRIETHYLPHOSPHINE GOLD; PALMARUMYCIN; PHOSPHOLE DERIVATIVE; PX 12; QUERCETIN; SELENITE; SELENODIGLUTATHIONE; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ARTICLE; BREAST CANCER; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG DESIGN; DRUG TARGETING; GLIOBLASTOMA; HUMAN; NONHUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; OXIDATION-REDUCTION; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 78650187554     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340610793358864     Document Type: Article

References (91)

1. Nguyen, P.; Awwad, R.T.; Smart, D.D.; Spitz, D.R.; Gius, D. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett., 2006, 236, 164-174. (Pubitemid 44262309)
2. Pennington, J.D.; Jacobs, K.M.; Sun, L.; Bar-Sela, G.; Mishra, M.; Gius, D. Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Curr. Pharm. Des., 2007, 13, 3368-3377. (Pubitemid 350201671)
3. Sun, Y.; Rigas, B. The thioredoxin system mediates redox-induced cell death in human colon cancer cells: Implications for the mechanism of action of anticancer agents. Cancer Res., 2008, 68, 8269-8277.
4. Arnér, E.S.; Holmgren, A. The thioredoxin system in cancer. Semin. Cancer Biol., 2006, 16, 420-426. (Pubitemid 44780139)
5. Smart, D.K.; Ortiz, K.L.; Mattson, D.; Bradbury, C.M.; Bisht, K.S.; Sieck, L.K.; Brechbiel, M.W.; Gius, D. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res., 2004, 64, 6716-6724. (Pubitemid 39297934)
6. Pennington, J.D.; Wang, T.J.; Nguyen, P.; Sun, L.; Bisht, K.; Smart, D.; Gius, D. Redox-sensitive signaling factors as a novel molecular targets for cancer therapy. Drug Resist. Update, 2005, 8, 322-330. (Pubitemid 41677715)
7. Urig, S.; Becker, K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin. Cancer Biol., 2006, 16, 452-465. (Pubitemid 44780136)
8. Powis. G.; Kirkpatrick, D.L.Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol., 2007, 7, 392-397. (Pubitemid 47289261)
9. Ott, I.; Qian, X.; Xu, Y.; Vlecken, D.H.; Marques, I.J.; Kubutat, D.; Will, J.; Sheldrick, W.S.; Jesse, P.; Prokop, A.; Bagowski, C.P. A gold(I) phosphine complex containing a naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angiogenesis inhibitor. J. Med. Chem., 2009, 52, 763-770.
10. Casini, A.; Gabbiani, C.; Sorrentino, F.; Rigobello, M.P.; Bindoli, A.; Geldbach, T.J.; Marrone, A.; Re, N.; Hartinger, C.G.; Dyson, P.J.; Messori, L. Emerging protein targets for anticancer metallodrugs: Inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. J. Med. Chem., 2008, 51, 6773-6781.
11. Shi, C.; Yu, L.; Yang, F.; Yan, J.; Zeng, H. A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines. Biochem. Biophys. Res. Commun., 2003, 309, 578-583. (Pubitemid 37083290)
12. Zhao, F.; Yan, J.; Deng, S.; Lan, L.; He, F.; Kuang, B.; Zeng, H. A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines. Cancer Lett., 2006, 236, 46-53.
13. Peng, Z.F.; Lan, L.X.; Zhao, F.; Li, J.; Tan, Q.; Yin, H.W.; Zeng, H.H. A novel thioredoxin reductase inhibitor inhibits cell growth and induces apoptosis in HL-60 and K562 cells. J Zhejiang Univ. Sci. B, 2008, 9, 16-21. (Pubitemid 351436993)
14. Xing, F.; Li, S.; Ge, X.; Wang, C.; Zeng, H.; Li, D.; and Dong, L. The inhibitory effect of a novel organoselenium compound BBSKE on the tongue cancer Tca8113 in vitro and in vivo. Oral Oncol., 2008, 44, 963-969.
15. Lan, L.; Zhao, F.; Wang, Y.; Zeng, H. The mechanism of apoptosis induced by a novel thioredoxin reductase inhibitor in A549 cells: Possible involvement of nuclear factor-kappaB-dependent pathway. Eur. J. Pharmacol., 2007, 555, 83-92. (Pubitemid 46048803)
16. Witte, A.B.; Anestal, K.; Jerremalm, E.; Ehrsson, H.; Arnér, E.S. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic. Biol. Med., 2005, 39, 696-703. (Pubitemid 41112110)
17. Hashemy, S.I.; Ungerstedt, J.S.; Zahedi, Avval.F.; Holmgren, A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J. Biol. Chem., 2006, 281, 10691-10697. (Pubitemid 43855490)
18. Fang, J.; Lu, J.; Holmgren, A. Thioredoxin reductase is irreversibly modified by curcumin: A novel molecular mechanism for its anticancer activity. J. Biol. Chem., 2005, 280, 25284-25290. (Pubitemid 40934623)
19. Biaglow, J.E.; Miller, R.A. The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy. Cancer Biol. Ther., 2005, 4, 6-13. (Pubitemid 41350919)
20. Tonissen, K.F.; Di, Trapani, G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol. Nutr. Food Res., 2009, 53, 87-103.
21. Mustacich, D.; Powis, G. Thioredoxin reductase. Biochem J., 2000, 346, 1-8. (Pubitemid 30113812)
22. Gladyshev, V.N.; Jeang, K.T. Stadtman, T.C. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc. Natl. Acad. Sci. USA, 1996, 93, 6146-6151. (Pubitemid 26190818)
23. Yoo, M.H.; Xu, X.M.; Carlson, B.A.; Gladyshev, V.N.; Hatfield, D.L. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol. Chem., 2006, 281, 13005-13008. (Pubitemid 43855208)
24. Koc, A.; Mathews, C.K.; Wheeler, L.J.; Gross, M.K.; Merrill, G.F. Thioredoxin is required for deoxyribonucleotide pool maintenance during S phase. J. Biol. Chem., 2006, 281, 15058-15063. (Pubitemid 43855094)
25. Baker, A.; Payne, C.M.; Briehi, M.M.; Powis, G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res., 1997, 57, 5162-7. (Pubitemid 27498136)
26. Watson, W.H.; Heilman, J.M.; Hughes, L.L.; Spielberger, J.C. Thioredoxin reductase-1 knock down does not result in thioredoxin- 1 oxidation. Biochem. Biophys. Res. Commun., 2008, 368, 832-836.
27. Gromer, S.; Schirmer, R.H.; Becker, K. The 58 kDa mouse selenoprotein is a BCNU-sensitive thioredoxin reductase. FEBS Lett., 1997, 412, 318-320. (Pubitemid 27321274)
28. Waksman, G.; Krishna, T.S.R.; Sweet, R.M.; Williams, C.H.Jr.; Kuriyan, J. Crystal structure of Escherichia coli thioredoxin reductase refined at 2 A resolution. Implications for a large conformational change during catalysis. J. Mol. Biol., 1994, 236, 800-816.
29. Russel, M.; Model, P. Sequence of thioredoxin reductase from Escherichia coli. Relationship to other flavoprotein disulfide oxidoreductases. J. Biol. Chem., 1988, 263, 9015-9019.
30. Zhong, L.; Arnér, E.S.; Ljung, J.; Aslund, F.; Holmgren, A. Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue. J. Biol. Chem., 1998, 273, 8581-8591. (Pubitemid 28176132)
31. Tamura, T.; Stadtman, T.C. A new selenoprotein from human lung adenocarcinoma cells: Purification, properties, and thioredoxin reductase activity. Proc. Natl. Acad. Sci. USA, 1996, 93, 1006-1011. (Pubitemid 26054364)
32. Lee, S.R.; Bar-Noy, S.; Kwon, J.; Levine, R.L.; Stadtman, T.C.; Rhee, S.G. Mammalian thioredoxin reductase: Oxidation of the Cterminal cysteine/selenocysteine active site forms a thioselenide, and replacement of selenium with sulfur markedly reduces catalytic activity. Proc. Natl. Acad. Sci. USA, 2000, 97, 2521-2526. (Pubitemid 30159203)
33. Zhong, L.; Arnér, E.S.; Holmgren, A. Structure and mechanism of mammalian thioredoxin reductase: The active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteineselenocysteine sequence. Proc. Natl. Acad. Sci. USA, 2000, 97, 5854-5859. (Pubitemid 30367488)
34. Sandalova, T.; Zhong, L.; Lindqvist, Y.; Holmgren, A.; Schneider, G. Three-dimensional structure of a mammalian thioredoxin reductase: Implications for mechanism and evolution of a selenocysteinedependent enzyme. Proc. Natl. Acad. Sci. USA, 2001, 98, 9533-9538. (Pubitemid 32769338)
35. Gromer, S.; Johansson, L.; Bauer, H.; Arscott, L.D.; Rauch, S.; Ballou, D.P.; Williams, CH.Jr.; Schirmer, R.H.; Arnér, E.S. Active sites of thioredoxin reductases: Why selenoproteins? Proc. Natl. Acad. Sci. USA, 2003, 100, 12618-12623. (Pubitemid 37339948)
36. Zhong, L.; Holmgren, A. Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. J. Biol. Chem., 2000, 275, 18121-18128. (Pubitemid 30414762)
37. Gromer, S.; Wissing, J.; Behne, D.; Ashman, K.; Schirmer, R.H.; Flohé, L.; Becker, K. A hypothesis on the catalytic mechanism of the selenoenzyme thioredoxin reductase. Biochem. J., 1998, 332, 591-592. (Pubitemid 28271894)
38. Metanis, N.; Keinan, E.; Dawson, P.E. Synthetic selenoglutaredoxin 3 analogues are highly reducing oxidoreductases with enhanced catalytic efficiency. J. Am. Chem. Soc., 2006, 128, 16684-16691. (Pubitemid 46032748)
39. Gromer, S.; Arscott, L.D.; Williams, C.H.Jr,; Schirmer, R.H.; Becker, K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J. Biol. Chem., 1998, 273, 20096-20101. (Pubitemid 28377564)
40. Urig, S.; Fritz-Wolf, K.; Réau, R.; Herold-Mende, C.; Tóth, K.; Davioud-Charvet, E.; Becker, K. Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases. Angew. Chem. Int. Ed. Engl., 2006, 45, 1881-1886. (Pubitemid 44105206)
41. Millet, R.; Urig, S.; Jacob, J.; Amtmann, E.; Moulinoux, J.P.; Gromer, S.; Becker, K.; Davioud-Charvet, E. Synthesis of 5-nitro-2- furancarbohydrazides and their cis-diamminedichloroplatinum complexes as bitopic and irreversible human thioredoxin reductase inhibitors. J. Med. Chem., 2005, 48, 7024-7039. (Pubitemid 41533125)
42. Becker, K.; Herold-Mende, C.; Park, J.J.; Lowe, G.; Schirmer, R.H. Human thioredoxin reductase is efficiently inhibited by (2,2':6',2''- terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy. J. Med. Chem., 2001, 44, 2784-2792. (Pubitemid 32879719)
43. Schallreuter, K.U.; Gleason, F.K.; Wood, J.M. The mechanism of action of the nitrosourea anti-tumor drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase. Biochim. Biophys. Acta., 1990, 1054, 14-20. (Pubitemid 20247791)
44. Mau, B.L.; Powis, G. Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin. Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity. Biochem. Pharmacol., 1992, 43, 1621-1627.
45. Lu, J.; Papp, L.V.; Fang, J.; Rodriguez-Nieto, S.; Zhivotovsky, B.; Holmgren, A. Inhibition of Mammalian thioredoxin reductase by some flavonoids: Implications for myricetin and quercetin anticancer activity. Cancer Res., 2006, 66, 4410-4418.
46. Chew, E.H.; Lu, J.; Bradshaw, T.D.; Holmgren, A. Thioredoxin reductase inhibition by antitumor quinols: A quinol pharmacophore effect correlating to antiproliferative activity. FASEB J., 2008, 22, 2072-2083. (Pubitemid 351811483)
47. Wipf, P.; Lynch, S.M.; Birmingham, A.; Tamayo, G.; Jiménez, A.; Campos, N.; Powis, G. Natural product based inhibitors of the thioredoxin- thioredoxin reductase system. Org. Biomol. Chem., 2004, 2, 1651-1658.
48. Lu, J.; Chew, E.H.; Holmgren, A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. USA, 2007, 104, 12288-12293. (Pubitemid 47206130)
49. Arnér, E.S.; Björnstedt, M.; Holmgren, A. 1-Chloro-2,4- dinitrobenzene is an irreversible inhibitor of human thioredoxin reductase. Loss of thioredoxin disulfide reductase activity is accompanied by a large increase in NADPH oxidase activity. J. Biol. Chem., 1995, 270, 3479-3482.
50. Ramanathan, R.K.; Kirkpatrick, D.L.; Belani, C.P.; Friedland, D.; Green, S.B.; Chow, H.H.; Cordova, C.A.; Stratton, S.P.; Sharlow, E.R.; Baker, A.; Dragovich, T. A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin- 1, in patients with advanced solid tumors. Clin. Cancer Res., 2007, 13, 2109-2114. (Pubitemid 46649879)
51. Magda, D.; Miller, R.A. Motexafin gadolinium: A novel redox active drug for cancer therapy. Semin. Cancer Biol., 2006, 16, 466-476. (Pubitemid 44780135)
52. Gallogly, M.M.; Mieyal. J.J. Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Curr. Opin. Pharmacol., 2007, 7, 381-391. (Pubitemid 47304000)
53. Mieyal, J.J.; Gallogly, M.M.; Qanungo, S.; Sabens, E.A.; Shelton, M.D. Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid. Redox Signal., 2008, 10, 1941-1988.
54. Sessler, J.L.; Tvermoes, N.A.; Guldi, D.M.; Mody, T.D.; Allen, W.E. One-electron reduction and oxidation studies of the radiation sensitizer gadolinium(III) texaphyrin (PCI-0120) and other water soluble metallotexaphyrins. J. Phys. Chem. A, 1999, 103, 787-794. (Pubitemid 129590525)
55. Rockwell, S.; Donnelly, E.; Liu, Y.; Tang, L. Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro. Int. J. Radiat. Oncol. Biol. Phys., 2002, 54, 536-541. (Pubitemid 35286823)
56. Evens, A.M.; Lecane, P.; Magda, D.; Prachand, S.; Singhal, S.; Nelson , J.; Miller, R.A.; Gartenhaus, R.B.; Gordon, L.I. Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood, 2005, 105, 1265-1273. (Pubitemid 40170902)
57. Magda, D.; Lecane, P.; Miller, R.A.; Lepp, C.; Miles, D.; Mesfin, M.; Biaglow, J.E.; Ho, V.V.; Chawannakul, D.; Nagpal, S.; Karaman, M.W.; Hacia, J.G. Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res., 2005, 65, 3837-3845. (Pubitemid 40616364)
58. Amato, R.J.; Jac, J.; Hernandez-McClain, J. Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: Phase II study results. Clin. Genitourin. Cancer, 2008, 6, 73-78.
59. Ford, J.M.; Seiferheld, W.; Alger, J.R.; Wu, G.; Endicott, T.J.; Mehta, M.; Curran, W.; Phan, S.C. Results of the phase I doseescalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys., 2007, 69, 831-838. (Pubitemid 47418404)
60. Rayman, M.P. The importance of selenium to human health. Lancet., 2000, 356, 233-241. (Pubitemid 30446984)
61. Lane, H.W.; Medina, D. Selenium concentration and glutathione peroxidase activity in normal and neoplastic development of the mouse mammary gland. Cancer Res., 1983, 43, 1558-1561. (Pubitemid 13122547)
62. Kumar, S.; Björnstedt, M.; Holmgren, A. Selenite is a substrate for calf thymus thioredoxin reductase and thioredoxin and elicits a large non-stoichiometric oxidation of NADPH in the presence of oxygen. Eur. J. Biochem., 1992, 207, 435-439.
63. Björnstedt, M.; Kumar, S.; Holmgren, A. Selenodiglutathione is a highly efficient oxidant of reduced thioredoxin and a substrate for mammalian thioredoxin reductase. J. Biol. Chem., 1992, 267, 8030-8034.
64. Gromer, S.; Gross, J.H. Methylseleninate is a substrate rather than an inhibitor of mammalian thioredoxin reductase. Implications for the antitumor effects of selenium. J. Biol. Chem., 2002, 277, 9701-9706. (Pubitemid 34968070)
65. Ip, C.; Thompson, H.J.; Zhu, Z.; Ganther, H.E. In vitro and in vivo studies of methylseleninic acid: Evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res., 2000, 60, 2882-2886. (Pubitemid 30395810)
66. Tibodeau, J.; Benson, L.; Isham, C.; Owen, W.; Bible, K. The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase. Antioxid. Redox Signal., 2009, 11, 1097-1106.
67. Cenas, N.; Nivinskas, H.; Anusevicius, Z.; Sarlauskas, J.; Lederer, F.; Arnér, E.S. Interactions of quinones with thioredoxin reductase: A challenge to the antioxidant role of the mammalian selenoprotein. J. Biol. Chem., 2004, 279, 2583-2592. (Pubitemid 38114244)
68. Zhao, R.; Masayasu, H.; Holmgren, A. Ebselen: A substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant. Proc. Natl. Acad. Sci. USA, 2002, 99, 8579-8584. (Pubitemid 34693604)
69. Nakamura, Y.; Feng, Q.; Kumagai, T.; Torikai, K.; Ohigashi, H.; Osawa, T.; Noguchi, N.; Niki, E.; Uchida, K. Ebselen, a glutathione peroxidase mimetic seleno-organic compound, as a multifunctional antioxidant. Implication for inflammation-associated carcinogenesis. J. Biol. Chem., 2002, 277, 2687-2694. (Pubitemid 34953296)
70. Hurley, L.H. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer, 2002, 2, 188-200. (Pubitemid 37328788)
71. Wang, X.; Zhang, J.; Xu, T. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo. Toxicol. Appl. Pharmacol., 2007, 218, 88-95. (Pubitemid 46026846)
72. Wang, X.; Zhang, J.; Xu, T. Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy. Eur. J. Pharmacol., 2008, 579, 66-73.
73. Zhang, J.; Lu, H. Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity. Free Radic. Biol. Med., 2007, 43, 1574-1583. (Pubitemid 350122981)
74. Shaw, C.F. Gold-based therapeutic agents. Chem. Rev., 1999, 99, 2589-2600.
75. Rigobello, M.P.; Folda, A.; Baldoin, M.C.; Scutari, G.; Bindoli, A. Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase. Free Radic. Res., 2005, 39, 687-695. (Pubitemid 40965396)
76. Rigobello, M.P.; Scutari, G.; Folda, A.; Bindoli, A. Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c. Biochem. Pharmacol., 2004, 67, 689-696. (Pubitemid 38125252)
77. Marzano, C.; Gandin, V.; Folda, A.; Scutari, G.; Bindoli, A.; Rigobello, M.P. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med., 2007, 42, 872-881. (Pubitemid 46274171)
78. Hickey, J.L.; Ruhayel, R.A.; Barnard, P.J.; Baker, M.V.; Berners- Price, S.J.; Filipovska, A. Mitochondria-targeted chemotherapeutics: The rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. J. Am. Chem. Soc., 2008, 130, 12570-12571.
79. Maheshwari, R.K.; Singh, A.K.; Gaddipati, J.; Srimal, R.C. Multiple biological activities of curcumin: A short review. Life Sci., 2006, 78, 2081-2087.
80. Han, S.S.; Chung, S.T.; Robertson, D.A.; Ranjan, D.; Bondada, S. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin. Immunol., 1999, 93, 152-161. (Pubitemid 29523391)
81. Han, S.S.; Keum, Y.S.; Seo, H.J.; Surh, Y.J. Curcumin suppresses activation of NF-kB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J. Biochem. Mol. Biol., 2002, 35, 337-342.
82. Singh, S.; Aggarwal, B.B. Activation of transcription factor NF-k B is suppressed by Curcumin (Diferulolylmethane). J. Biol. Chem., 1995, 270, 24995-5000.
83. Iqbal, M.; Sharma, S.D.; Okazaki, Y.; Fujisawa, M.; Okada, S. Dietary supplementation of curcumin enhances antioxidant and Phase II metaholizing enzymes in ddY male mice: Possihie role in protection against chemical carcinogenesis and toxicity. Pharmacol. Toxicol., 2003, 92, 33-38. (Pubitemid 36238075)
84. Ramanathan, R.K.; Kirkpatrick, D.L.; Belani, C.P.; Friedland, D.; Green, S.B.; Chow, H.H.; Cordova, C.A.; Stratton, S.P.; Sharlow, E.R.; Baker, A.; Dragovich, T. A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin- 1, in patients with advanced solid tumors. Clin. Cancer Res., 2007, 13, 2109-2114. (Pubitemid 46649879)
85. Jordan, B.F.; Runquist, M.; Raghunand, N.; Gillies, R.J.; Tate, W.R.; Powis, G.; Baker, A.F. The thioredoxin-1 inhibitor 1- methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. Clin. Cancer Res., 2005, 11, 529-536. (Pubitemid 40116876)
86. Oblong, J.E.; Chantler, E.L.; Gallegos, A.; Kirkpatrick, D.L.; Chen, T.; Marshall, N.; Powis, G. Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues. Cancer Chemother. Pharmacol., 1994; 34, 434-438. (Pubitemid 24261285)
87. Kirkpatrick, D.L.; Kuperus, M.; Dowdeswell, M.; Potier, N.; Donald, L.J.; Kunkel, M.; Berggren, M.; Angulo, M.; Powis, G. .Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem. Pharmacol., 1998, 55, 987-994. (Pubitemid 28167720)
88. Baker, A.F.; Dragovich, T.; Tate, W.R.; Ramanathan, R.K.; Roe, D.; Hsu, C.H.; Kirkpatrick, D.L.; Powis, G. The antitumor thioredoxin- 1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J. Lab. Clin. Med., 2006, 147, 83-90. (Pubitemid 43189000)
89. Deng, S.J.; Kuang, B.; Zhou, X.; Yan, J.; Zhao, F.; Jia, X.Y.; Zeng, H.H. The in vitro antitumor effect of 1,2-[bis(1,2- benzisoselenazolone-3(2H)- ketone)]-ethane. J. Pek. Univ. (Health Sciences), 2003, 35, 108-109.
90. Tan, Q.; Li, J.; Yin, H.W.; Wang, L.H.; Tang, W.C.; Zhao F.; Liu X.M.; Zeng, H.H. Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo. Invest. New Drugs, 2010, 28, 205-215.
91. Li, J.; Fang, J.C.; Zeng, H.H. Therapeutic effect of combination therapy with ethaselen and cisplatin or fluorouracil on gastric cancer cell BGC-823. Chin. J. New Drugs Clin. Rem., 2008, 27, 834-843.